STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXCM
  4. [Form 4] DEXCOM INC Insider Trading Activity

Dexcom (DXCM) CFO now holds 150,390 shares after tax withholding

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

DEXCOM INC (DXCM) reported that EVP and Chief Financial Officer Jereme M. Sylvain had 1,451 shares of common stock withheld on 2026-08-22 to satisfy tax withholding and remittance obligations tied to the net settlement of restricted stock units; this was not an open-market sale. After this withholding, he holds 150,390 shares directly, including 87,094 unvested restricted stock units with grants on March 8, 2026, 2025 and 2024 that vest through dates extending to March 8, 2029.

Positive

  • None.

Negative

  • None.
Insider Sylvain Jereme M
Role EVP, Chief Financal Officer
Type Security Shares Price Value
Tax Withholding Common Stock F1, F2 1,451 $92.34 $134K
Holdings After Transaction: Common Stock — 150,390 shares (Direct)
Footnotes (2)
  1. F1. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.
  2. F2. Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
Shares withheld for tax 1,451 shares Shares withheld on 2026-08-22 to cover tax withholding and remittance obligations
Withholding price per share $92.34 per share Reported price associated with the 1,451 shares withheld
Shares held after transaction 150,390 shares Directly held by the reporting person following the 2026-08-22 transaction
Unvested restricted stock units 87,094 units Unvested RSUs included in post-transaction holdings
RSUs granted March 8, 2026 48,774 units Vest through March 8, 2029
RSUs granted March 8, 2025 (to 2028) 23,937 units Vest through March 8, 2028
RSUs granted March 8, 2025 (to 2027) 5,699 units Vest through March 8, 2027
RSUs granted March 8, 2024 8,684 units Vest through March 8, 2027
restricted stock units financial
"connection with the net settlement of restricted stock units and does not represe"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
net settlement financial
"to cover tax withholding and remittance obligations in connection with the net s"
tax withholding financial
"required to be withheld by the Issuer to cover tax withholding and remittance ob"
Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.
unvested restricted stock units financial
"Included in this number are 87,094 unvested restricted stock units, 48,774 of wh"

FAQ

What transaction did DXCM CFO Jereme M. Sylvain report on this Form 4?
He reported that 1,451 shares of Dexcom common stock were withheld on 2026-08-22 to cover tax withholding and remittance obligations related to the net settlement of restricted stock units, coded as a Form 4 transaction type F.

Was the DXCM Form 4 transaction by the CFO an open-market sale?
No. The filing states the 1,451 shares represent shares required to be withheld by Dexcom to cover tax withholding and remittance obligations in connection with net settlement of restricted stock units and does not represent a sale by the reporting person.

How many DXCM shares does the CFO hold after this Form 4 transaction?
After the tax-withholding transaction, Jereme M. Sylvain directly holds 150,390 shares of Dexcom common stock. This total includes 87,094 unvested restricted stock units with various grant and vesting schedules described in the filing.

What unvested restricted stock units does the DXCM CFO have outstanding?
He has 87,094 unvested restricted stock units: 48,774 granted March 8, 2026 vesting through March 8, 2029; 23,937 granted March 8, 2025 vesting through March 8, 2028; 5,699 granted March 8, 2025 vesting through March 8, 2027; and 8,684 granted March 8, 2024 vesting through March 8, 2027.

Is the DXCM CFO’s Form 4 transaction under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false), and the footnotes describe the transaction solely as tax withholding in connection with net settlement of restricted stock units.

What price per share is associated with the DXCM Form 4 withholding transaction?
The transaction reports a price of $92.34 per share for the 1,451 shares withheld to satisfy tax withholding and remittance obligations related to the restricted stock unit net settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sylvain Jereme M
(Last)(First)(Middle)
6340 SEQUENCE DRIVE
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Chief Financal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/22/2026F1,451(1)D$92.34150,390(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.
2. Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
Remarks:
/s/ Jereme M. Sylvain08/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR